Please use this identifier to cite or link to this item: https://hdl.handle.net/11499/10863
Title: Molecular characterization of drug resistance in hepatitis B viruses isolated from patients with chronical infection in Turkey
Authors: Asan, A.
Sayan, M.
Akhan, S.
Koruk, S.T.
Aygen, B.
Sirmatel, F.
Eraksoy, H.
Keywords: Antiviral Drug Resistance
Chronic Hepatitis B
HBsAg
HBV Polymerase
Hepatitis B Virus
Sequence Analysis
adefovir
alanine aminotransferase
aspartate aminotransferase
hepatitis B surface antigen
hepatitis B(e) antigen
lamivudine
peginterferon
telbivudine
tenofovir
adult
aged
amino acid substitution
Article
enzyme linked immunosorbent assay
female
gene mutation
gene sequence
hepatitis B
Hepatitis B virus
Hepatitis B virus genotype D
human
major clinical study
male
prevalence
real time polymerase chain reaction
virus isolation
virus load
Publisher: Kowsar Medical Publishing Company
Abstract: Background: Hepatitis B virus (HBV) has a high mutation rate due to its unusual replication strategy leading to the production of a large number of virions with single and double mutations. The mutations, in turn, are associated with the development of drug resistance to nucleos(t)ide analogs (NUCs) in patients before and during NUCs therapy. Objectives: The current study aimed at investigating the molecular characterization of HBV in Turkish patients with chronic hepatitis B (CHB) infection. Methods: Polymerase chain reaction (PCR) amplification and direct sequencing procedures were used to analyze mutations. The detected drug resistance mutations were divided into the nucleos(t)ide analogs primary, partial, and compensatory resistance groups. The amino acid substitutions of hepatitis B surface antigen (HBsAg) were categorized into antiviral drug - associated potential vaccine - escape mutations (ADAPVEMs) and typical HBsAg amino acid substitutions, which included hepatitis B hyperimmunoglobulin (HBIg) - selected escape mutation, vaccine escape mutation, hepatitis B misdiagnosis, and immune - selected amino acid substitutions. Results: The number of patients included in the study was 528 out of which 271 (51.3%) were treatment - naive and 351 (66.3%) were hepatitis B e antigen (HBeAg) - negative. Moreover, 325 (61.6%) were males with a mean age of 38 years (range: 18 - 69). Primary, partial, and compensatory resistance to NUCs was reported in 174 (32.9%) patients. Six different ADAPVEM motifs were determined in both treatment - naive and treatment - experienced patients, namely, sF161L/rtI169X, sE164D/rtV173L, sL172L/rtA181T, sL173F/rtA181V, sS195M/rtM204V, and sS196L/rtM204I. The prevalence of ADAPVEMs and typical HBsAg escape mutations was 5.3% (n = 28) and 34.8% (n = 184), respectively. Conclusions: The analysis of drug resistance should constitute a fundamental part of the follow - up period of patients with CHB undergone treatment with NUCs. The surveillance of development of drug resistance mutations, while receiving treatment for hepatitis B is of paramount importance to monitor and control the emerging resistance. © 2018, Hepatitis Monthly.
URI: https://hdl.handle.net/11499/10863
https://doi.org/10.5812/hepatmon.12472
ISSN: 1735-143X
Appears in Collections:Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
Tıp Fakültesi Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection

Files in This Item:
File SizeFormat 
Molecular Characterization.pdf136.12 kBAdobe PDFView/Open
Show full item record



CORE Recommender

SCOPUSTM   
Citations

3
checked on Sep 30, 2024

WEB OF SCIENCETM
Citations

4
checked on Sep 24, 2024

Page view(s)

52
checked on Aug 24, 2024

Download(s)

22
checked on Aug 24, 2024

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.